Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*

Abstract:
Minerva Biotechnology, a leading nanotechnology, cancer and stem cell development company today announced a major breakthrough in a cancer target that is widely expressed in human cancers. Minerva used its proprietary nanoparticle technology to elucidate a key molecular mechanism that is involved in cancer cell growth and metastasis. The study, published today in the journal PLoS ONE (www.plosone.org/doi/pone.0002054) focuses on a cell surface receptor, called MUC1, which according to extensive scientific literature is aberrantly expressed on 75% of all human solid tumors - 96% of breast cancers, 47% of prostate cancers, as well as high percentages of ovarian, colorectal, non-small cell lung, and pancreatic cancers. Circulating MUC1 is currently used as a diagnostic marker for breast cancer and over expression also has been shown by many studies to be correlated with poor clinical outcome.

Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*

Boston, MA | Posted on May 5th, 2008

Using its unique nanoparticle research platform, Minerva has shown that MUC1 is actually cleaved to a new form, called MUC1* (‘star'). Once cleaved, MUC1* dimerizes with itself and other growth factor receptors through binding of a newly discovered ligand for MUC1*, called NM23. Binding and dimerization then acts to activate the tumor to unregulated cell growth, invasion and metastasis. Blocking MUC1* dimerization and NM23 binding leads to cancer cell death. Minerva has identified both antibody-based and small molecule therapeutics that disable the receptor and block cancer cell growth.

This new discovery may also lead to better diagnostics. In collaboration with a leading diagnostic reference lab in California, Minerva has shown that MUC1* is expressed to much higher levels than MUC1 in a variety of human tumor tissues, and in the future could provide both diagnostic and prognostic information on tumor development.

####

About Minerva Biotechnology
Minerva is a US-headquartered company focused on a next generation novel nanoparticle platform. Minerva enjoys a broad and dominant intellectual property position in the field of nanotechnology with over 100 patents or patent applications filed with US and worldwide rights reserved. Minerva’s intellectual property covers a wide range of uses for its nanoparticle systems in fields as diverse as drug discovery, proteomics, opto-electronics and nano-scale biosensors. Minerva has focused squarely on drug discovery and diagnostics for cancer and stem cell treatments and has used its nanotechnology in-house to expedite novel target identification and new drug development.

For more information, please click here

Contacts:
Minerva Biotechnology
Cynthia Bamdad
617-821-8773

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanomedicine

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Announcements

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project